James Choe, MD
Endocrinology, Diabetes & Metabolism · del City, OKNPI 1093075707
Payments from drug & device makers
Across 517 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- AstraZeneca$1K
- Novo Nordisk$785
- Dexcom, Inc.$780
- Abbott$669
- Sanofi-aventis U.S. LLC$579
- plus $4K from 33 others
What the payments were for
- Food & beverage$9,63199%
- Education$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 103 | $1,718 |
| AstraZeneca | 49 | $1,104 |
| Novo Nordisk | 53 | $785 |
| Dexcom, Inc. | 44 | $780 |
| Abbott | 30 | $669 |
| Sanofi-aventis U.S. LLC | 29 | $579 |
| Xeris Pharmaceuticals, Inc. | 25 | $521 |
| Insulet Corporation | 27 | $465 |
| Tandem Diabetes Care, Inc. | 21 | $452 |
| Merck | 18 | $301 |
| Boehringer Ingelheim | 13 | $250 |
| Corcept Therapeutics | 11 | $226 |
| Mannkind Corporation | 10 | $186 |
| Sequel Med Tech, LLC | 8 | $175 |
| Ascensia Diabetes Care US Inc. | 7 | $148 |
| Recordati_rare_diseases_inc. | 6 | $147 |
| Ultragenyx Pharmaceutical Inc. | 7 | $143 |
| Nevro Corp. | 6 | $131 |
| AbbVie | 6 | $123 |
| Bayer | 5 | $88 |
| Amgen(2 entities) | 4 | $81 |
| Cequr Corporation | 2 | $78 |
| Medtronic(2 entities) | 4 | $74 |
| Kyowa Kirin, Inc. | 3 | $74 |
| Exact Sciences | 4 | $60 |
| Vistapharm, Inc. | 3 | $46 |
| GSK | 3 | $46 |
| Radius Health, Inc. | 2 | $45 |
| Halozyme Inc | 2 | $37 |
| Antares Pharma, Inc. | 2 | $34 |
| Zealand Pharma US, Inc. | 2 | $28 |
| Rhythm Pharmaceuticals, Inc. | 1 | $27 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Novartis | 1 | $19 |
| Eisai Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Tosoh Bioscience, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$216
How this compares
$9,750 in reported general payments places this provider in the 75th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 150 | $237,474 |
| JardianceEmpagliflozin | 141 | $165,977 |
| MounjaroTirzepatide | 107 | $161,373 |
| TrulicityDulaglutide | 84 | $112,513 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 38 | $74,389 |
| FarxigaDapagliflozin Propanediol | 72 | $68,972 |
| JanuviaSitagliptin Phosphate | 53 | $59,022 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 48 | $49,426 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $47,758 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $44,321 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $37,554 |
| Bydureon BciseExenatide Microspheres | 37 | $30,467 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $28,813 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $14,653 |
| Novolog FlexpenInsulin Aspart | 48 | $14,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,718 | $273,886191 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $785 | $250,130183 claims |
| Boehringer IngelheimJardiance | $250 | $165,977141 claims |
| AstraZenecaFarxiga | $1,104 | $68,97272 claims |
| MerckJanuvia | $301 | $59,02253 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $579 | $49,42648 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $20 | $2,758248 claims |
| AbbVieSynthroid | $123 | $1,22435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in del City
- Lubna MirzaNorman$837K
- Cassie SmithEdmond$629K
- Matthew DraelosEdmond$392K
- Robert ScofieldOklahoma City$189K
- Jonea LimOklahoma City$172K
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Christian MangrumOklahoma City$54K
- Elie AbedTulsa$27K
- Vaqar AhmadMidwest City$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.